日本批准Bylvay治疗罕见肝病 PFIC, 提供新的治疗选择。 Japan approves Bylvay for rare liver disease PFIC, offering new treatment option.

日本已批准Bylvay(odvixibat)治疗累进家庭内血清胆固醇(PFIC),这是一种罕见的肝病。 Bylvay (odevixibat) has received approval in Japan for the treatment of progressive familial intrahepatic cholestasis (PFIC), a rare liver disease. 获得日本药品和医疗设备署的核准,对有这种病症的病人来说是一个重大发展,提供了一种新的治疗选择。 The approval, granted by Japan's Pharmaceuticals and Medical Devices Agency, marks a significant development for patients with this condition, offering a new therapeutic option. Bylvay是一种丁酸转移抑制剂,旨在降低丁酸水平,缓解痒和肝脏损伤等症状。 Bylvay, a bile acid transporter inhibitor, aims to reduce bile acid levels and alleviate symptoms such as itching and liver damage. 日本现在向符合资格的病人提供这种药物,扩大这种罕见疾病的治疗机会。 The drug is now available in Japan for eligible patients, expanding access to treatment for this rare disorder.